Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2023 | 1547 | 1.330 |
Why?
|
| Philadelphia Chromosome | 4 | 2022 | 117 | 1.170 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2023 | 431 | 0.890 |
Why?
|
| Neoplasm, Residual | 3 | 2023 | 1007 | 0.610 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 5649 | 0.330 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2020 | 1403 | 0.300 |
Why?
|
| Mediastinal Neoplasms | 2 | 2017 | 402 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9276 | 0.210 |
Why?
|
| Graft vs Host Disease | 2 | 2024 | 3025 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2021 | 383 | 0.150 |
Why?
|
| Transplantation Conditioning | 2 | 2024 | 1588 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2018 | 237 | 0.130 |
Why?
|
| Yttrium Radioisotopes | 1 | 2016 | 107 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 11712 | 0.110 |
Why?
|
| Sulfonamides | 1 | 2024 | 1977 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 2116 | 0.110 |
Why?
|
| Leukemia | 1 | 2021 | 1520 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 3602 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1628 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1895 | 0.090 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 935 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2017 | 1056 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 5643 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2049 | 0.070 |
Why?
|
| Italy | 2 | 2021 | 841 | 0.070 |
Why?
|
| Prognosis | 4 | 2021 | 29658 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2803 | 0.060 |
Why?
|
| Disease Progression | 1 | 2021 | 13502 | 0.060 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2024 | 121 | 0.060 |
Why?
|
| Vincristine | 2 | 2017 | 1039 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20080 | 0.050 |
Why?
|
| Humans | 19 | 2024 | 760621 | 0.050 |
Why?
|
| Azacitidine | 1 | 2024 | 334 | 0.050 |
Why?
|
| Prednisone | 2 | 2017 | 1565 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2022 | 101 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2024 | 646 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2017 | 2221 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2017 | 2209 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 9185 | 0.040 |
Why?
|
| Oncogenes | 1 | 2024 | 1220 | 0.040 |
Why?
|
| Carmustine | 1 | 2018 | 138 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 424 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 1122 | 0.040 |
Why?
|
| Ligands | 1 | 2024 | 3276 | 0.040 |
Why?
|
| Etoposide | 1 | 2018 | 630 | 0.030 |
Why?
|
| Melphalan | 1 | 2018 | 420 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1722 | 0.030 |
Why?
|
| Radioimmunotherapy | 1 | 2016 | 91 | 0.030 |
Why?
|
| Cytarabine | 1 | 2018 | 696 | 0.030 |
Why?
|
| Bleomycin | 1 | 2017 | 495 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2023 | 2693 | 0.030 |
Why?
|
| Remission Induction | 1 | 2021 | 2392 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 4810 | 0.030 |
Why?
|
| Leucovorin | 1 | 2017 | 641 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 8552 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13630 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2023 | 6068 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 693 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2022 | 2860 | 0.030 |
Why?
|
| Adult | 6 | 2023 | 219994 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1454 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 6828 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4550 | 0.020 |
Why?
|
| Acute Disease | 1 | 2021 | 7269 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2018 | 65017 | 0.020 |
Why?
|
| Methotrexate | 1 | 2017 | 1719 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2017 | 1504 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2017 | 1057 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14372 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 29932 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2023 | 80372 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6544 | 0.020 |
Why?
|
| Risk | 1 | 2017 | 9631 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2016 | 10182 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 11152 | 0.010 |
Why?
|
| Research Design | 1 | 2017 | 6180 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 8056 | 0.010 |
Why?
|
| Young Adult | 2 | 2018 | 58741 | 0.010 |
Why?
|
| Aged | 3 | 2018 | 169152 | 0.010 |
Why?
|
| Adolescent | 2 | 2018 | 87810 | 0.010 |
Why?
|
| Middle Aged | 3 | 2018 | 220352 | 0.010 |
Why?
|
| Incidence | 1 | 2017 | 21392 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 81208 | 0.010 |
Why?
|
| Male | 3 | 2018 | 359744 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39261 | 0.010 |
Why?
|
| Female | 3 | 2018 | 391270 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 167963 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 58995 | 0.010 |
Why?
|
Concepts
(88)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_